Regenxbio Share Price Today

REGENXBIO sura-vec data shows majority NPDR improvement at 3 years

Majority of Dose Level 3 NPDR participants achieved >2-step DRSS improvement at 3 years. No vision-threatening events or additional diabetic retinopathy treatments required. No intraocular inflammation observed with short-course topical steroids.

Regenxbio settles Sarepta patent litigation for $39 million

Regenxbio and UPenn settled patent litigation with Sarepta and Catalent for $39 million. Payment due within 10 days of effective date, resolving claims on Patents-in-Suit. Agreement includes covenant not to sue over existing ELEVIDYS and AAVrh74 capsid patents.

Johnson Fistel investigates REGENXBIO for alleged fiduciary breaches

Johnson Fistel investigates REGENXBIO officers for alleged fiduciary breaches. Eligible shareholders held RGNX stock continuously since before February 9, 2022. Allegations include concealing safety risks for RGX-111 Phase I/II trial. FDA placed RGX-111 on clinical hold on January 28, 2026, after tumor identification. RGNX stock fell 17.8% to $11.01 following the clinical hold announcement.

Johnson Fistel investigates REGENXBIO after FDA places RGX-121 on clinical hold

Johnson Fistel investigates REGENXBIO Inc. (NASDAQ: RGNX) for potential securities fraud. FDA placed RGX-121 gene therapy on clinical hold after MRI findings in five participants. Company does not expect to resubmit biologics license application for RGX-121 soon. Previous clinical hold on RGX-111 program led to expanded MRI monitoring protocols.

FDA places clinical hold on Regenxbio RGX-121 after spine MRI findings

FDA placed clinical hold on RGX-121 after asymptomatic spine MRI findings in five participants. Regenxbio shares fell 23.79% to $8.170 in premarket trading following the update. Company does not expect to resubmit BLA in near term; evaluating additional imaging data. All five affected participants remain clinically stable with no brain masses identified. Other pipeline programs for Duchenne and retinal diseases remain on track.

Regenxbio Q2 Results: Conference Call Set for August 6 to Discuss Financials

Regenxbio Inc. scheduled a conference call for August 6, 2026, to present its second-quarter 2026 financial results and operational updates. The biotechnology firm will discuss performance metrics and progress in its gene therapy pipeline, including collaborations with AbbVie and Nippon Shinyaku. Investors can access the live webcast and a subsequent replay via the company’s investor relations portal.